$LLY (Eli Lilly and Company)

$LLY {{ '2016-01-28T12:52:40+0000' | timeago}} • Announcement

Drug giant $LLY reported a 12% rise in 4Q15 earnings on lower asset impairment, restructuring charges, and higher margin. Net income rose to $478.4MM or $0.45 per share from $428.5MM or $0.40 per share last year. Revenue rose 5% to $5.38Bil. But, non-GAAP EPS slid 5% to $0.78, due to termination costs for evacetrapib and basal insulin peglispro.

$LLY {{ '2017-09-25T13:18:33+0000' | timeago}} • Announcement

Geisinger and Boehringer Ingelheim, on behalf of its partnership with $LLY, announced that they will create a model to predict the three major outcomes associated with type 2 diabetes. The new model will allow to predict the complications from cardiovascular death, kidney failure and hospitalization for heart failure.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$LLY {{ '2017-09-12T14:09:14+0000' | timeago}} • Announcement

$LLY announced that Jardiance tablets reduced the risk of cardiovascular death in people with Type 2 diabetes and established cardiovascular disease independent of blood sugar control. Jardiance also reduced the risk of cardiovascular death compared to placebo regardless of background Metformin or Sulfonylurea use.

$LLY {{ '2017-09-11T15:56:35+0000' | timeago}} • Announcement

$LLY  to present data for Olumiant (baricitinib) for the treatment of moderate-to-severe atopic dermatitis at the annual European Academy of Dermatology and Venereology Congress (EADV) in Geneva during Sept 13-17, 2017. Lilly is also set to present data for its psoriasis drug Taltz in EADV.

$LLY {{ '2017-09-11T15:50:35+0000' | timeago}} • Announcement

$LLY presented data from Phase 3 RANGE study of Cyramza (ramucirumab) for the treatment of urothelial cancer. Lilly added that Cyramza significantly increased progression-free survival (PFS) by almost 25% compared with placebo. RANGE overall survival (OS) data are immature and final OS results are currently expected in mid-2018.

$LLY {{ '2017-09-11T15:30:38+0000' | timeago}} • Announcement

$LLY stated that its migraine treatment drug Lasmiditan reduces pain. Lilly presented the data related to this study in the 18th Congress of the International Headache Society (IHC) in Vancouver. The company plans to submit a NDA for Lasmiditan to FDA in 2H18.

$LLY {{ '2017-09-08T15:16:54+0000' | timeago}} • Announcement

$LLY reported that its migraine treatment drug Galcanezumab had positive long-term safety results from a 12-month, open-label study. The detailed results will be presented at a conference in Vancouver on Sept 8, 2017. Lilly plans to submit a Biologics License Application (BLA) to FDA for Galcanezumab in 2H17.

$LLY {{ '2017-09-07T17:35:51+0000' | timeago}} • Announcement

As part of the streamlining initiatives, $LLY expects to eliminate the majority of the employees through a U.S. voluntary early retirement program. Lilly also plans to close certain sites, including R&D offices in Bridgewater, New Jersey and Shanghai, China. The company plans to invest in new medicines and drive growth.

$LLY {{ '2017-09-07T17:22:37+0000' | timeago}} • Announcement

$LLY to cut 3,500 jobs globally. The drugmaker expects annualized savings of $500MM beginning in 2018. Lilly expects to incur charges of approx $1.2Bil pre-tax or $0.80 per share after-tax. As a result of the streamlining initiatives, 2017 GAAP EPS is expected to be reduced by the amount of the charges and non-GAAP EPS outlook is unchanged.

$LLY {{ '2017-09-06T14:31:48+0000' | timeago}} • Announcement

$LLY to present new data for two of its migraine drugs Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC) in Vancouver during Sept. 7-10. Lasmiditan was originally developed by Eli Lilly, which was licensed to CoLucid in 2005. Lilly completed the acquisition of CoLucid in March 2017.

$LLY {{ '2017-08-30T13:53:36+0000' | timeago}} • Announcement

$LLY to resubmit the New Drug Application for rheumatoid arthritis medication Baricitinib, to the U.S. FDA, before the end of January 2018. Last month, Lilly and its development and marketing partner $INCY announced that resubmission of Baricitinib will take at least 18 months.

$LLY {{ '2017-08-29T15:04:04+0000' | timeago}} • Announcement

$LLY to present Phase 3 data for two of its cancer treatment drugs at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain during Sept 8-12, 2017. Results from Phase 3 studies of breast cancer drug Abemaciclib and urothelial cancer drug Ramucirumab have been selected for oral presentation.

$LLY {{ '2017-08-14T18:46:16+0000' | timeago}} • Webcast

$LLY expects to begin the Phase 3 study for baricitinib (rheumatoid arthritis drug) and psoriatic arthritis in 2018. Also, the company expects an executive order from Washington administration regarding the drug pricing in the second half of 2017.

$LLY {{ '2017-08-04T14:22:07+0000' | timeago}} • Announcement

$LLY reported that late stage clinical trials of its migraine drug Lasmiditan were positive. In March 2017, Lilly completed the acquisition of CoLucid Pharmaceuticals, including Lasmiditan, which was out-licensed by Lilly. The company plans to file a New Drug Application to the FDA in the second half of 2018.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$LLY {{ '2017-07-25T13:14:16+0000' | timeago}} • Announcement

Drugmaker $LLY reported a jump in its profit for the second quarter 2017, boosted by new pharma products sales and higher realized prices. Profit climbed 35% to $1.01Bil and GAAP EPS surged 34% to $0.91 versus a year ago. Revenue grew 8% to $5.82Bil and non-GAAP EPS spiked up 29% to $1.11.

$LLY {{ '2017-07-25T12:32:52+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q2 2017 Highlights

$LLY {{ '2017-07-24T19:31:07+0000' | timeago}} • Announcement

As a result of the deal signed with Nektar on co-developing autoimmune drug NKTR-358, $LLY expects a charge of about $0.09 per share to its 2017 earnings. Eli Lilly cut down its 2017 GAAP EPS outlook by $0.09 to $2.51-2.61 from its previous outlook of $2.60-2.70 and it didn't change the estimate for non-GAAP EPS because of the Nektar partnership.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY to co-develop $NKTR's autoimmune drug NKTR-358. Under the deal terms, Eli Lilly will pay Nektar Therapeutics an upfront payment of $150MM and up to $250MM if development and regulatory milestones are achieved. Nektar to complete Phase 1 clinical development and will bear 25% of Phase 2 cost. $LLY will bear 75% of the Phase 2 development cost.

Recent Transcripts

SGYP (Synergy Pharmaceuticals, Inc.)
Thursday, September 7 2017 - 8:30pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
TSRO (Tesaro, Inc.)
Tuesday, August 8 2017 - 8:15pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
FGEN (FibroGen, Inc.)
Monday, August 7 2017 - 9:00pm
ARQL (ArQule Inc.)
Friday, August 4 2017 - 1:00pm
SUPN (Supernus Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 1:00pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
SCMP (Sucampo Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
IMGN (ImmunoGen, Inc.)
Friday, July 28 2017 - 12:00pm
RARE (Ultragenyx Pharmaceutical Inc.)
Thursday, July 27 2017 - 9:00pm
SNSS (Sunesis Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 6:00pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
TRIB (Trinity Biotech plc)
Thursday, July 20 2017 - 3:00pm

AlphaGraphics you may like